US FDA advises COVID vaccine makers to develop shots aimed at XBB.1.5 variant

person holding syringe and vaccine bottle

The U.S. Food and Drug Administration (FDA) said it has advised manufacturers that are updating their COVID-19 vaccines to develop monovalent shots to target the XBB.1.5 subvariant.

So-called monovalent, or single-target vaccines, would be a change from the most recent bivalent COVID boosters that targeted both the original and Omicron strains of the coronavirus.

The FDA’s advice comes a day after its panel of experts unanimously recommended that the updated COVID shots being developed for a fall vaccination campaign target one of the currently dominant XBB coronavirus variants.

COVID vaccine makers Pfizer /BioNTech, Moderna  and Novavax  are already developing versions of their respective vaccines to target XBB.1.5 and other currently circulating subvariants.

Novavax’s XBB.1.5 COVID vaccine candidate is being manufactured at commercial scale, with plans for it to be in the market for the fall campaign, the company said on Friday.

Discover more from The Dispatch

Subscribe now to keep reading and get access to the full archive.

Continue reading

Verified by MonsterInsights